| Title |
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
|
|---|---|
| Published in |
The Lancet, May 2012
|
| DOI | 10.1016/s0140-6736(12)60768-5 |
| Pubmed ID | |
| Authors |
Peter Sandercock, Joanna M Wardlaw, Richard I Lindley, Martin Dennis, Geoff Cohen, Gordon Murray, Karen Innes, Graham Venables, Anna Czlonkowska, Adam Kobayashi, Stefano Ricci, Veronica Murray, Eivind Berge, Karsten Bruins Slot, Graeme J Hankey, Manuel Correia, Andre Peeters, Karl Matz, Phillippe Lyrer, Gord Gubitz, Stephen J Phillips, Antonio Arauz |
Login to access the Attention Digest and the Sentiment Analysis related to this output.
An error occurred while generating this chart. Please try again later.
No score history available for this output yet. Please try again later.
X Demographics
The data shown below were collected from the profiles of 66 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 9 | 14% |
| United States | 8 | 12% |
| Mexico | 7 | 11% |
| Spain | 6 | 9% |
| Canada | 3 | 5% |
| France | 2 | 3% |
| Japan | 2 | 3% |
| Argentina | 2 | 3% |
| Kuwait | 1 | 2% |
| Other | 11 | 17% |
| Unknown | 15 | 23% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 49 | 74% |
| Practitioners (doctors, other healthcare professionals) | 8 | 12% |
| Scientists | 5 | 8% |
| Science communicators (journalists, bloggers, editors) | 4 | 6% |
Mendeley demographics
The data shown below were compiled from readership statistics for 962 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 7 | <1% |
| South Africa | 5 | <1% |
| United States | 4 | <1% |
| Canada | 4 | <1% |
| Brazil | 3 | <1% |
| Japan | 3 | <1% |
| Switzerland | 3 | <1% |
| Spain | 3 | <1% |
| Australia | 2 | <1% |
| Other | 11 | 1% |
| Unknown | 917 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 148 | 15% |
| Other | 121 | 13% |
| Student > Bachelor | 97 | 10% |
| Student > Postgraduate | 92 | 10% |
| Student > Ph. D. Student | 88 | 9% |
| Other | 218 | 23% |
| Unknown | 198 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 510 | 53% |
| Neuroscience | 66 | 7% |
| Agricultural and Biological Sciences | 43 | 4% |
| Biochemistry, Genetics and Molecular Biology | 19 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 15 | 2% |
| Other | 81 | 8% |
| Unknown | 228 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 151. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 December 2025.
All research outputs
#344,989
of 34,637,473 outputs
Outputs from The Lancet
#3,411
of 52,301 outputs
Outputs of similar age
#1,391
of 215,515 outputs
Outputs of similar age from The Lancet
#28
of 519 outputs
Altmetric has tracked 34,637,473 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 52,301 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 63.4. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 215,515 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 519 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.